{'fraction_non_alphanumeric': 0.024279210925644917, 'fraction_numerical': 0.006828528072837633, 'mean_word_length': 6.368715083798882, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia

Abstract. Drugs that inhibit cholesterol synthesis have recently been released for lowering LDL‐cholesterol levels. The current study examines the effect of one of these drugs, lovastatin, alone and in combination with cholestyramine on postprandial fat metabolism in five patients with severely elevated LDL‐cholesterol and normal triglyceride levels (< 1.8 mmol 1‐1) and in five patients with similarly elevated LDL‐cholesterol and mildly elevated triglyceride levels (1.8 to 2.7 mmoll‐1). In the group of patients with normal triglyceride levels, neither lovastatin alone nor in combination with cholestyramine had any effect on postprandial lipoprotein levels, while profoundly decreasing LDL‐cholesterol levels. This provides evidence that LDL and postprandial lipoproteins are cleared by different mechanisms. In the group of five patients with mildly elevated triglyceride levels, in addition to LDL‐cholesterol lowering, lovastatin significantly lowered VLDL‐cholesterol, fasting triglyceride and postprandial lipoprotein levels. Thus in patients with mild hypertriglyceridaemia, lovastatin may have another favourable effect on the lipoprotein system in addition to LDL‐cholesterol lowering.